We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Age Alters Diagnostic Performance of Cardiac Troponin

By LabMedica International staff writers
Posted on 20 Sep 2022
Print article
Image: High-sensitivity cardiac troponin I: relying on the sex-specific 99th percentile upper reference limit of cardiac troponin may incorrectly suggest myocardial infarction (MI) in older adults with suspected heart attacks (Photo courtesy of Blood Tests in London)
Image: High-sensitivity cardiac troponin I: relying on the sex-specific 99th percentile upper reference limit of cardiac troponin may incorrectly suggest myocardial infarction (MI) in older adults with suspected heart attacks (Photo courtesy of Blood Tests in London)

The guideline-recommended thresholds for increased high-sensitivity cardiac troponin I (hs-cTnI), indicating myocardial injury and potential infarction, performed at a similar sensitivity around 80% in people across age groups.

Relying on the sex-specific 99th percentile upper reference limit of cardiac troponin may incorrectly suggest myocardial infarction (MI) in older adults with suspected heart attacks, though no diagnostic approach has emerged as a better alternative.

Cardiovascular Scientists at the University of Edinburgh (Edinburgh, UK) and their colleagues assessed the diagnostic accuracy of high-sensitivity cardiac troponin I at presentation for the diagnosis of type 1, type 2, or type 4b myocardial infarction across three age groups (<50, 50–74, and ≥75 years) using guideline-recommended sex-specific and age-adjusted 99th centile thresholds. This was a secondary analysis of a multicenter trial across 10 hospitals in Scotland of consecutive patients with suspected myocardial infarction. The study included 46,435 consecutive patients aged 18 to 108 years (mean, 61±17 years), 5,216 (11%) had a diagnosis of myocardial infarction.

The team reported that thresholds for increased high-sensitivity cardiac troponin I (hs-cTnI), indicating myocardial injury and potential infarction, performed at a similar sensitivity around 80% in people across age groups. However, specificity for MI fell with increasing age: 98.3% in people under 50 years, 95.5% in those 50-74, and 82.6% in those age 75 and older. For that oldest group, age-adjusted 99th percentile thresholds improved specificity to 91.3% at the cost of a major loss in sensitivity (down from 81.6% to 55.9%) for an overall positive predictive value (PPV) of 59.3%. Other alternative hs-cTnI analyses they tried for people over 75 years old, applying a universal rule-in threshold of 64 ng/L, and factoring in the person's cardiovascular comorbidities, also failed to take MI diagnosis to an acceptable balance of sensitivity and specificity similar to that seen in younger patients.

Atul Anand, MD, PhD, a cardiovascular scientist and a lead author of the study, said, “No approach achieved parity in the diagnosis between older and younger patients with specificity and PPV reducing with advancing age regardless of the threshold adopted, and alternatives to the guideline-recommended approach resulted in a marked reduction in sensitivity in older persons.”

The authors concluded that age alters the diagnostic performance of cardiac troponin, with reduced specificity and positive predictive value in older patients when applying the guideline-recommended or age-adjusted 99th centiles. Individualized diagnostic approaches rather than the adjustment of binary thresholds are needed in an aging population. The study was published on September 15, 2022 in the journal Circulation.

Related Links:
University of Edinburgh

New
Gold Supplier
Vaginosis Test
VAGINAL PANEL REALTIME PCR KIT
New
Human Anti-S. Cerevisiae Antibodies Test
ASCA-CHEK
New
Automatic Fecal Analyzer
TEX760
New
Dual-Channel Optical Coagulation Analyzer
Sensa2

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: Special blood test could determine if patient has early stage breast cancer and if the cancer is unlikely to return (Photo courtesy of USC)

Simple Blood Draw Could Revolutionize Early Breast Cancer Detection

Breast cancer is the most prevalent form of cancer in the world, affecting one in eight women over their lifetime. Since 1976 when the American Cancer Society endorsed mammography X-rays, the technique... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.